Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.

ABSTRACT: Antibody-drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA), a cytotoxic payload, and a chemical linker that binds both. To this regard, most efforts have been focused on target identification, antibody design and linker optimization, but other relevant aspects for clinical development have not received the necessary attention. In this article using data from approved ADCs, we evaluated all characteristics of these agents, including payload physicochemical properties, in vitro potency, drug antibody ratio (DAR), exposure-response relationships, and clinical development strategies. We suggest that compounds with be

SUBMITTER: Lopez de Sa A 

PROVIDER: S-EPMC10717055 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature